All In Biotech

Drug Trial Radar · NCT02389621

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 215 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

215

Actual

Start

Jun 15, 2015

Primary completion

Apr 5, 2017

Study completion Apr 19, 2017

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Mar 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the efficacy of lusutrombopag with placebo for the treatment of thrombocytopenia in patients with chronic liver disease who are undergoing elective invasive procedures.

Conditions

  • Chronic Liver Disease
  • Thrombocytopenia

Interventions

  • LusutrombopagDrug

    Tablets for oral administration

  • PlaceboDrug

    Tablets for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7 Days After the Primary Elective ProcedureTime frame: From Randomization to 7 days after the invasive procedure, up to approximately 21 days.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.